ASX Announcement

18 November 2026

ASX Limited

Market Announcements Office

39 Martin Place

SYDNEY NSW 2000

Re: Healius Limited ('HLS'): Late lodgement of Appendix 3Y – Paul Anderson

The Company wishes to notify the ASX that a Director's Appendix 3Y is being lodged outside the required timeframes under the ASX Listing Rules.

We now enclose the Appendix 3Y for lodgement and have outlined below an explanation as to why this occurred.

On 26 October 2026, an adviser's platform sold 8,694 shares held indirectly by the Director without his knowledge or authority. Upon becoming aware of the transaction, the Director promptly repurchased the same number of shares, restoring his holding to the number disclosed in his previous Appendix 3Y.

As neither the Director nor the Company was notified of the disposal at the time it occurred, the Appendix 3Y was not lodged within the five-business-day period required by ASX Listing Rule 3.19A.2.

The Company considers this to be an isolated incident and that its existing arrangements with Directors for notification of changes in their interests (including under its 'Policy on Trading in Healius Securities') are appropriate. The Director has also engaged with his adviser regarding appropriate processes to be applied should a similar situation arise in the future.

This announcement has been authorised for release by the Managing Director and CEO.

For further information please contact:

Investor Enquiries

Andrew Thomson
Chief Financial Officer
Healius Limited
investor.relations@healius.com.au

Media Enquiries

Susannah Rands
Head of Communications
Healius Limited
media@healius.com.au

About Healius Limited

For over 30 years Healius has been one of Australia's leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Through its unique footprint of centres and its 8,500+ employees, Healius provides Australia-wide specialty pathology services to consumers and their referring practitioners.

For personal use only

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HEALIUS LIMITED
ABN	24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Anderson
Date of last notice	27 October 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	The Director has an indirect interest in fully paid ordinary shares in Healius Limited acquired by the Tuis Farm Family Trust as he is a beneficiary of the Trust.
Date of change	26 October 2026 inadvertent sale 17 November 2026 re-purchase
No. of securities held prior to change	Direct 37,837 Ordinary Shares 4,469,109 Performance Rights 117,433 Service Rights Indirect 344,843 Ordinary Shares
Class	Fully paid ordinary shares
Number acquired	8694
Number disposed	8694
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$0.43 per share inadvertently sold $0.585 per share re-purchased

+ See chapter 19 for defined terms.

For personal use only

No. of securities held after change	Direct 37,837 Ordinary Shares 4,469,109 Performance Rights 117,433 Service Rights Indirect 344,843 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The securities were mistakenly sold by the Director's adviser. The Director re-purchased the securities on becoming aware of the decrease in holding.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Authorised by:
Kylie Brown
Company Secretary
Date: 18 November 2026

+ See chapter 19 for defined terms.

For personal use only